GCP
ALLO icon

GSA Capital Partners’s Allogene Therapeutics ALLO Stock Holding History

GSA Capital Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Sell
151,722
-462,276
-75% -$927K 0.02% 1110
2025
Q4 		$841K Buy
613,998
+431,119
+236% +$569K 0.07% 461
2025
Q3 		$227K Sell
182,879
-309,242
-63% -$369K 0.02% 1361
2025
Q2 		$556K Buy
492,121
+8,353
+2% +$11.1K 0.04% 853
2025
Q1 		$706K Buy
+483,768
New +$912K 0.06% 562
2024
Q3 		– Sell
-835,342
Closed -$1.95M – 1565
2024
Q2 		$1.95M Buy
+835,342
New +$2.46M 0.14% 159
2024
Q1 		– Sell
-20,518
Closed -$66K – 1573
2023
Q4 		$66K Sell
20,518
-106,294
-84% -$301K 0.01% 1413
2023
Q3 		$402K Buy
+126,812
New +$556K 0.03% 922
2023
Q1 		– Sell
-251,384
Closed -$1.58M – 1449
2022
Q4 		$1.58M Buy
251,384
+219,538
+689% +$2.03M 0.2% 53
2022
Q3 		$344K Buy
+31,846
New +$433K 0.05% 832
2022
Q2 		– Sell
-148,804
Closed -$1.36M – 1364
2022
Q1 		$1.36M Buy
148,804
+33,989
+30% +$354K 0.18% 83
2021
Q4 		$1.71M Buy
+114,815
New +$2.03M 0.22% 46
2021
Q3 		– Sell
-13,951
Closed -$364K – 1386
2021
Q2 		$364K Buy
+13,951
New +$398K 0.04% 817
2021
Q1 		– Sell
-11,273
Closed -$285K – 1070
2020
Q4 		$285K Buy
+11,273
New +$367K 0.05% 767
2020
Q1 		– Sell
-10,622
Closed -$276K – 1026
2019
Q4 		$276K Buy
+10,622
New +$293K 0.03% 1079

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's ALLO Position: Q1 2026 in Review

GSA Capital Partners reduced its Allogene Therapeutics (ALLO) stake by 75% in Q1 2026, selling an estimated $927K and leaving 151,722 shares worth $370K. The position accounts for 0.02% of the portfolio, ranked #1110.

GSA Capital Partners first reported a position in ALLO in Q4 2019 and has held it in 15 quarters since. The position peaked at $1.95M in Q2 2024. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • GSA Capital Partners held 151,722 shares of Allogene Therapeutics worth $370K as of Q1 2026.
  • GSA Capital Partners sold 462,276 Allogene Therapeutics shares in Q1 2026, an estimated $927K.
  • Allogene Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1110 holding.
  • GSA Capital Partners first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 15 quarters since.
  • GSA Capital Partners's Allogene Therapeutics position peaked at $1.95M in Q2 2024.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.